Nebulised treprostinil prodrug

Drug Profile

Nebulised treprostinil prodrug

Alternative Names: INS-1009

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Insmed
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 03 Sep 2016 Pharmacodynamics data from preclinical studies in Pulmonary arterial hypertension presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 03 Sep 2016 Pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 01 Sep 2016 Clinical data from a phase I trial in Pulmonary arterial hypertension (In volunteers) presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top